CTI BioPharma Corp. (CTIC)

0.95
0.02 1.88
NASDAQ
Prev Close 0.97
Open 0.97
Day Low/High 0.94 / 0.97
52 Wk Low/High 0.60 / 5.36
Volume 237.89K
Exchange NASDAQ
Shares Outstanding 57.98B
Market Cap 56.43M
Div & Yield N.A. (N.A)
CTI BioPharma To Present At The 18th Annual Needham Healthcare Conference On Wednesday, Apr. 10

CTI BioPharma To Present At The 18th Annual Needham Healthcare Conference On Wednesday, Apr. 10

SEATTLE, April 3, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference at 9:20 a.

CTI BioPharma Reports Fourth Quarter And Full Year 2018 Financial Results And Recent Highlights

CTI BioPharma Reports Fourth Quarter And Full Year 2018 Financial Results And Recent Highlights

SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018.

CTI BioPharma To Present At Oppenheimer's 29th Annual Healthcare Conference On Tuesday, Mar. 19

CTI BioPharma To Present At Oppenheimer's 29th Annual Healthcare Conference On Tuesday, Mar. 19

SEATTLE, March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29 th Annual Healthcare Conference at 4:30 p.

CTI BioPharma To Present At The 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

CTI BioPharma To Present At The 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

SEATTLE, Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp.

CTI BioPharma Receives $10 Million Milestone Payment For TRISENOX®

CTI BioPharma Receives $10 Million Milestone Payment For TRISENOX®

SEATTLE, Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp.

CTI BioPharma Receives Results Of The CHMP Oral Explanation For Pacritinib In The Treatment Of Myelofibrosis And Provides Development Update

CTI BioPharma Receives Results Of The CHMP Oral Explanation For Pacritinib In The Treatment Of Myelofibrosis And Provides Development Update

- Company announces continuation of PAC203 study following third interim review -

CTI BioPharma Announces Completion Of Enrollment In The Phase 2 PAC203 Study Of Pacritinib

CTI BioPharma Announces Completion Of Enrollment In The Phase 2 PAC203 Study Of Pacritinib

- Optimal dose determination from the PAC203 study expected in mid-2019 with topline data expected in the third quarter of 2019 -

CTI BioPharma Provides Program Update Following Regulatory Feedback From The U.S. FDA On Pacritinib Development

CTI BioPharma Provides Program Update Following Regulatory Feedback From The U.S. FDA On Pacritinib Development

- CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia -

CTI BioPharma Announces Restructuring Plan

CTI BioPharma Announces Restructuring Plan

- Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development -

CTI BioPharma Provides Program Update Following Regulatory Feedback On Pacritinib Development From The European Medicines Agency

CTI BioPharma Provides Program Update Following Regulatory Feedback On Pacritinib Development From The European Medicines Agency

- European regulatory opinion on marketing authorization application (MAA) for pacritinib now expected in the first quarter of 2019 -

CTI BioPharma Reports Third Quarter 2018 Financial Results

CTI BioPharma Reports Third Quarter 2018 Financial Results

-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time-

CTI BioPharma To Report Third Quarter 2018 Financial Results On November 1, 2018

CTI BioPharma To Report Third Quarter 2018 Financial Results On November 1, 2018

SEATTLE, Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp.

First Week Of CTIC November 16th Options Trading

First Week Of CTIC November 16th Options Trading

Investors in CTI BioPharma Corp saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

First Week Of CTIC July 20th Options Trading

First Week Of CTIC July 20th Options Trading

Investors in CTI BioPharma Corp saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Stocks with insider trader activity include LPNT, PATK and CTIC

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

Law Offices of Howard G. Smith reminds investors of the upcoming  April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Stocks with insider trader activity include SPTN, FL and CTIC

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Stocks with insider trader activity include ATRS, CMT and CTIC

Insider Trading Alert - DRE And CTIC Traded By Insiders

Insider Trading Alert - DRE And CTIC Traded By Insiders

Stocks with insider trader activity include DRE, CTIC and WAFD

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CTI BioPharma Corp.

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors Of Important Deadline In Class Action - CTIC

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors Of Important Deadline In Class Action - CTIC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp.

CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold for Himself

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold for Himself

In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CTI BioPharma Corp. - CTIC

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CTI BioPharma Corp. - CTIC

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CTI BioPharma Corp.

Kirby McInerney LLP Advises CTI BioPharma Corp. Investors Of Potential Claims

Kirby McInerney LLP Advises CTI BioPharma Corp. Investors Of Potential Claims

The law firm of Kirby McInerney LLP announced today that it has been retained by an investor to pursue claims against CTI BioPharma Corp.

TheStreet Quant Rating: D (Sell)